SIR4156

SIR4156 is a small molecule activator of nicotinamide phosphoribosyltransferase (NAMPT) being developed by Sironax Ltd. NAMPT is the rate-limiting enzyme in the NAD+ salvage pathway, which is essential for maintaining cellular energy homeostasis and NAD+ levels. By activating NAMPT, SIR4156 aims to restore energy balance in cells affected by age-related degenerative processes. The drug is currently in Phase 1 clinical development, with studies investigating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult and elderly participants. It is being targeted toward a broad range of conditions, including neurological and muscular degenerative diseases, metabolic diseases, cardiovascular diseases, and inflammatory conditions.